Talimogene Laherparepvec (Imlygic)

Haymarket Media
|

Slideshow

  • Talimogene Slide 1

  • Talimogene Slide 2

  • Talimogene Slide 3

  • You can skip this ad in 3 seconds.

  • Talimogene Slide 4

  • Talimogene Slide 5

  • Talimogene Slide 6

  • You can skip this ad in 3 seconds.

  • Talimogene Slide 7

  • Talimogene Slide 8

  • Talimogene Slide 9

  • You can skip this ad in 3 seconds.

  • Talimogene Slide 10

  • Talimogene Slide 11

  • Talimogene Slide 12

  • You can skip this ad in 3 seconds.

  • Talimogene Slide 13

  • Talimogene Slide 14

  • Talimogene Slide 15

  • You can skip this ad in 3 seconds.

  • Talimogene Slide 16

  • Talimogene Slide 17

  • Talimogene Slide 18

  • You can skip this ad in 3 seconds.

  • Talimogene Slide 19

  • Talimogene Slide 20

  • Talimogene Slide 21

  • You can skip this ad in 3 seconds.

  • Talimogene Slide 22

  • Talimogene Slide 23

  • Talimogene Slide 24

  • You can skip this ad in 3 seconds.

  • Talimogene Slide 25

  • Talimogene Slide 26

 

This slideshow reviews talimogene laherparepvec (Imlygic), indicated for unresectable cutaneous, subcutaneous, and nodal lesions in patients with recurrent melanoma after initial surgery/

Table of Contents

Slide 4: Dosage and Administration
Slide 11: Cautions, Effects, and Interactions
Slide 18: What to Tell Your Patient
Slide 26: Reference 

 

  • Latest News Your top articles for Saturday

  • Haymarket Medical NetworkTop Picks

  • Loading...

    Continuing Medical Education (CME/CE) Courses

    Show More